(CTNM) Contineum Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
CTNM: Neuroscience, Inflammation, Immunology
Contineum Therapeutics, Inc. (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oral small molecule therapies targeting high unmet needs in neuroscience, inflammation, and immunology. The companys lead candidate, PIPE-791, is a brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), currently in development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). PIPE-791s ability to cross the blood-brain barrier positions it as a promising candidate for central nervous system (CNS) disorders. Additionally, the company is advancing PIPE-307, a selective M1 receptor inhibitor, for depression and relapse-remitting MS, and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, rebranded from Pipeline Therapeutics, Inc. in November 2023, has been operational since its incorporation in 2009 and is headquartered in San Diego, California. The companys strategic focus on CNS and inflammatory diseases aligns with growing demand for innovative therapies in these areas.
3-month forecast: Based on
Additional Sources for CTNM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CTNM Stock Overview
Market Cap in USD | 166m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2024-04-05 |
CTNM Stock Ratings
Growth 5y | -40.2% |
Fundamental | -61.6% |
Dividend | 0.0% |
Rel. Strength Industry | -56.5 |
Analysts | 4.5/5 |
Fair Price Momentum | 5.44 USD |
Fair Price DCF | 12.15 USD |
CTNM Dividends
No Dividends PaidCTNM Growth Ratios
Growth Correlation 3m | -94.5% |
Growth Correlation 12m | -54.5% |
Growth Correlation 5y | -54.5% |
CAGR 5y | -55.38% |
CAGR/Max DD 5y | -0.77 |
Sharpe Ratio 12m | -1.42 |
Alpha | -67.41 |
Beta | 1.94 |
Volatility | 65.36% |
Current Volume | 27.4k |
Average Volume 20d | 42.4k |
As of March 14, 2025, the stock is trading at USD 7.14 with a total of 27,400 shares traded.
Over the past week, the price has changed by +10.87%, over one month by -7.15%, over three months by -49.11% and over the past year by -55.38%.
No, based on ValueRay Fundamental Analyses, Contineum Therapeutics (NASDAQ:CTNM) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -61.57 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTNM as of March 2025 is 5.44. This means that CTNM is currently overvalued and has a potential downside of -23.81%.
Contineum Therapeutics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy CTNM.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CTNM Contineum Therapeutics will be worth about 6.4 in March 2026. The stock is currently trading at 7.14. This means that the stock has a potential downside of -10.22%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 29.3 | 309.7% |
Analysts Target Price | 28.7 | 301.5% |
ValueRay Target Price | 6.4 | -10.2% |